Home » Newsletters » BioWorld Science

BioWorld Science

July 27, 1999

View Archived Issues

Abbott makes major strides in R&D during Q2

Competitive Technologies' ribozymes offer promise in gene therapy approaches

Cerus initiates phase III U.S. trial of platelet pathogen inactivation system

Alza expands promotion of Ditropan XL for overactive bladder

Idec Pharmaceuticals development highlights during second quarter

AHP's pneumococcal conjugate vaccine receives priority review status

Clinical program initiated for CEP-1347 in neurodegenerative disease therapy

Fujisawa initiates enrollment in phase III RA trial of Prograf

Phase I trial results reported for MSI pulmonary delivery of morphine

Patient enrollment completed in Anogesic phase III trial

Progenics awarded two grants from NIH for HIV programs

Novel class of acetylcholine receptor ligands discovered by Sibia researchers

Cytokine production inhibitors from SB particularly useful for inflammation, osteoporosis

Chroman-based beta3-adrenoceptor agonists in development at Bayer

Novel BZ-site GABA-A receptor ligands disclosed by Sanofi-Synthelabo

New agents for glaucoma disclosed by Alcon in recent patent literature

Bayer presents new anticancer compounds that inhibit Raf kinase

Antiobesity compounds in the Novartis pipeline

Gacyclidine displays therapeutic window of up to one hour in rat model of focal cerebral ischemia

Dual antioxidant/nNOS inhibitor effective in animal models of cerebral ischemia and brain injury

Nitrosylated alpha-adrenoceptor antagonists as potential agents for impotence

FDA requests additional data to support n-docosanol NDA

BM-113: pharmacokinetics and metabolism in rats following oral and intravenous dosing

Magainin's Locilex cream not approvable says FDA

Elan to develop Antegren for chronic treatment of MS

Continuous infusion of toborinone preferable in heart failure developing after cardiac surgery

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...